The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Renosen Pharmaceuticals Pvt Ltd
SENORES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Renosen Pharmaceuticals Private Limited, part of the promoter group of Senores Pharmaceuticals, acquired 2,500 equity shares in the company through the open market on August 28, 2025. The promoter group's holding marginally increased from 27,06,219 shares (5.88%) to 27,08,719 shares (5.88%) of the total share capital. The disclosure is filed under Regulation 29(2) of SEBI Takeover Regulations. Total equity share capital of Senores Pharmaceuticals remains 4,60,53,588 shares of Rs. 10 each.
The acquisition is very small (2,500 shares) and does not materially change the promoter group's stake, which remains at 5.88%. This is a routine compliance filing indicating continued promoter confidence, with no meaningful impact on shareholding structure or stock price expected.